vTv Therapeutics Past Earnings Performance
Past criteria checks 0/6
vTv Therapeutics's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 34.1% per year.
Key information
-11.2%
Earnings growth rate
21.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -34.1% |
| Return on equity | -124.3% |
| Net Margin | -2,017.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation
Aug 24
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?
May 11vTv Therapeutics GAAP EPS of -$0.04
Aug 16vTv stock soars 18% on $10M equity investment by CinRx Pharma
Jul 25We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully
Aug 17The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares
Mar 03vTv Therapeutics inks licensing deal for HPP971, shares up 11%
Dec 15MacAndrews & Forbes buys 625K shares of vTv Therapeutics
Dec 11Revenue & Expenses Breakdown
How vTv Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -20 | 13 | -3 |
| 31 Mar 24 | 1 | -21 | 12 | 0 |
| 31 Dec 23 | 0 | -20 | 12 | 0 |
| 30 Sep 23 | 0 | -22 | 12 | 8 |
| 30 Jun 23 | 0 | -19 | 12 | 8 |
| 31 Mar 23 | 0 | -17 | 10 | 0 |
| 31 Dec 22 | 2 | -19 | 12 | 0 |
| 30 Sep 22 | 2 | -21 | 15 | 0 |
| 30 Jun 22 | 5 | -18 | 14 | 0 |
| 31 Mar 22 | 5 | -16 | 15 | 0 |
| 31 Dec 21 | 4 | -13 | 11 | 0 |
| 30 Sep 21 | 10 | -5 | 9 | 0 |
| 30 Jun 21 | 7 | -5 | 8 | 0 |
| 31 Mar 21 | 7 | -8 | 7 | 0 |
| 31 Dec 20 | 6 | -8 | 7 | 0 |
| 30 Sep 20 | 0 | -15 | 7 | 0 |
| 30 Jun 20 | 0 | -17 | 8 | 0 |
| 31 Mar 20 | 2 | -17 | 9 | 0 |
| 31 Dec 19 | 3 | -18 | 9 | 0 |
| 30 Sep 19 | 7 | -15 | 9 | 0 |
| 30 Jun 19 | 11 | -11 | 9 | 0 |
| 31 Mar 19 | 11 | -12 | 9 | 0 |
| 31 Dec 18 | 12 | -9 | 9 | 0 |
| 30 Sep 18 | 8 | -11 | 10 | 0 |
| 30 Jun 18 | 5 | -14 | 10 | 0 |
| 31 Mar 18 | 2 | -15 | 11 | 0 |
| 31 Dec 17 | 0 | -16 | 11 | 0 |
| 30 Sep 17 | 0 | -16 | 11 | 0 |
| 30 Jun 17 | 0 | -16 | 10 | 0 |
| 31 Mar 17 | 0 | -17 | 10 | 0 |
| 31 Dec 16 | 1 | -16 | 10 | 0 |
| 30 Sep 16 | 1 | -15 | 10 | 0 |
| 30 Jun 16 | 1 | -16 | 10 | 0 |
| 31 Mar 16 | 1 | -22 | 10 | 0 |
| 31 Dec 15 | 1 | -27 | 9 | 0 |
| 30 Sep 15 | 1 | -32 | 9 | 0 |
| 30 Jun 15 | 1 | -34 | 8 | 0 |
| 31 Mar 15 | 2 | -31 | 9 | 0 |
| 31 Dec 14 | 2 | -36 | 12 | 0 |
| 31 Dec 13 | 1 | -48 | 8 | 0 |
Quality Earnings: VTVT is currently unprofitable.
Growing Profit Margin: VTVT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTVT is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare VTVT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: VTVT has a negative Return on Equity (-124.33%), as it is currently unprofitable.